Anti-tumor immunity is triggered by tumor-associated antigens, and results in the activation of innate and adaptive effector cells, such as natural killer cells and CD8+ T-cells, which directly eliminate tumor cells upon activation. This evidence concerns the gene CD8A and neoplasm.